Neurocrine Acknowledges Potential Need For More Indiplon Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm said its review of an “approvable” and a “not approvable” letter for different formulations of the insomnia agent suggest FDA may seek additional studies.